Bob Bradway, Amgen CEO (Alamy Reuters)
February 8, 2022 02:24 PM EST
Pharma

Af­ter Q4 sales sink, Am­gen CEO Bob Brad­way de­tails lofty growth strat­e­gy for 2030: Can he pull it off?

Nicole DeFeudis

Editor

While Am­gen boast­ed a 2% rev­enue boost last year, that growth was large­ly dri­ven by prof­its from the com­pa­ny’s Covid-19 man­u­fac­tur­ing deal with Eli Lil­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

FDA lifts hold on En­trada's Duchenne drug af­ter two years

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times